Advances in laboratory monitoring of direct oral anticoagulants
10.3760/cma.j.issn.1009-9158.2017.07.015
- VernacularTitle:直接口服抗凝药物的实验室监测进展
- Author:
Xuelian WU
;
Chenxue QU
;
Juhua DAI
;
Liping LI
- Keywords:
Anticoagulants;
Administration;
oral;
Drug monitoring;
Plasma concentration;
Laboratories
- From:
Chinese Journal of Laboratory Medicine
2017;40(7):544-547
- CountryChina
- Language:Chinese
-
Abstract:
Direct oral anticoagulants,include direct thrombin inhibitor and direct factor Xa inhibitor.As the pharmacokinetics and pharmacodynamics of these drugs are known,their plasma concentration is not food-effective,and theoretically it is not necessary to monitor routinely.However, clinical practice in recent years has shown that anticoagulant effect of DOACs is required to evaluate in patients with thrombosis, major bleeding, emergency surgery, hepatic/renal dysfunction and other special situations.Recent studies have shown that routine coagulation assays such as activated partial thromboplastin time(APTT) and thrombin time(TT) can be used as laboratory screening tests for direct thrombin inhibitor dabigatran and prothrombin time(PT) can be used as laboratory screening test for direct factor Xa inhibitor rivaroxaban.DOAC′s quantitative measurements include dilute thrombin time(dTT),hemoclot thrombin inhibitor (HTI),ecarin clotting time (ECT) and ecarin chromogenic assay (ECA) for direct thrombin inhibitor and anti-FXa assay(rivaroxaban calibration) for rivaroxaban.Laboratories should establish their own monitoring range when performing these assays.
